MKI67 and neoplasm: KYSE30 cells cotransplanting with activated CAFs significantly enhanced tumor volume (Figure 9A), increased the expression of proliferative biomarker‐Ki67, lymphangiogenic biomarker‐LYVE‐1, and microvessel biomarker‐CD31 (Figure 9B), compared with KYSE30 tumors alone.